

DEC 02 2002

FORM PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No.: UCSD-07017	Serial No.: 09/788,110		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary)  (37 CFR § 1.98(b))				Applicant: Maurizio Zanetti			
				Filing Date: 02/15/01		Group Art Unit:	
U.S. PATENT DOCUMENTS							
Examiner Initials	Cite No.	Serial / Patent Number	Issue Date	Applicant / Patente	Class	Subclass	Filing Date
Sel	1	4,622,952	11/18/86	Gordon			
	2	5,658,234	8/19/97	Dunlavy			
	3	6,106,829	8/22/00	He et al.			
	4	6,168,946	1/2/01	Houghton et al.			DEC 03 2002
	5	5,635,188	6/3/97	Bystryn			TECH CENTER 1600/2000
OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)							
Sel	6	Matthes et al. (1983) "A Pigmentation-associated, Differentiation Antigen of Human Melanoma Defined by a Precipitating Antibody in Human Serum," Int. J. Cancer 32:717					
	7	Tai et al. (1983) "Glycoproteins as Differentiation Markers in Human Malignant Melanoma and Melanocytes," Cancer Res. 43:2773					
	8	Thomson et al. (1988) "Differentiation Antigens of Melanocytes and Melanoma: Analysis of Melanosome and Cell Surface Markers of Human Pigmented Cells with Monoclonal Antibodies," J. Invest. Dermatol. 90:459					
	9	Zakian (1995) "Telomeres: Beginning to Understand the End," Science 270:1601					
	10	Blackburn and Gall (1978) "A Tandemly Repeated Sequence at the Termini of the Extrachromosomal Ribosomal RNA Genes in Tetrahymena," J. Mol. Biol. 120:33					
	11	Oka et al. (1980) "Inverted terminal repeat sequence in the macronuclear DNA of <i>Styloynchia pustulata</i> ," Gene 10:301					
	12	Klobutcher et al. (1981) "All gene-sized DNA molecules in four species of hypotrichs have the same terminal sequence and an unusual 3' terminus," Proc. Natl. Acad. Sci. 78:3015					
	13	Wellinger et al. (1993) "Origin Activation and Formation of Single-Strand TG <sub>1,3</sub> Tails Occur Sequentially in Late S Phase on a Yeast Linear Plasmid," Mol. Cell. Biol. 13:4057					
	14	Minev et al. (2000) "Cytotoxic T cell immunity against telomerase reverse transcriptase in humans," Proc. Natl. Acad. Sci. USA 97:4796-4801					
	15	Vonderheide et al. (1999) "The Telomerase Catalytic Subunit Is a Widely Expressed Tumor-Associated Antigen Recognized by Cytotoxic T Lymphocytes," Immunity 10:673-679					
	16	Blackburn (1992) "Telomerases," Ann. Rev. Biochem. 61:1139-129					
	17	Blackburn (1991) "Structure and function of telomeres," Nature 350:569-73					
	18	Greider (1994) "Mammalian telomere dynamics: healing, fragmentation shortening and stabilization," Curr. Opin. Genet. Devel. 4:203-11					
	19	Counter et al. (1992) "Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity," EMBO J. 11:1921-29					
	20	Buchkovich et al. (1996) "Telomerase Regulation during Entry into the Cell Cycle in Normal Human T Cells," Mol. Biol. Cell 7:1443-54					
	21	Weng et al. (1996) "Regulated Expression of Telomerase Activity in Human T Lymphocyte Development and Activation," J. Exp. Med. 183:2471-9					
	22	Weng et al. (1997) "Telomere lengthening and telomerase activation during human B cell differentiation," Proc. Natl. Acad. Sci. USA 94:10827-32					
	23	Lee et al. (1998) "Essential role of mouse telomerase in highly proliferative organs," Nature 392:569-74					
	24	Kim et al. (1994) "Specific Association of Human Telomerase Activity with Immortal Cells and Cancer," Science 266:2011-5					
	25	Meyerson et al. (1997) "hEST2, the Putative Human Telomerase Catalytic Subunit Gene, is Up-Regulated in Tumor Cells and during Immortalization," Cell 90:785-795					
Examiner: <i>A. L. G.</i>				Date Considered: 8/23/04			
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

FORM PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary)  (37 CFR § 1.98(b))		Attorney Docket No.: UCSD-02424	
		Serial No.: 08/723,052	
		Applicant: Mario Chojkier <i>et al.</i>	
		Filing Date: 09/30/96	Group Art Unit:
OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)			
Sec	26	Bodnar <i>et al.</i> (1998) "Extension of Life-Span by Introduction of Telomerase into Normal Human Cells," <i>Science</i> 279:349-52	
OPTC	27	Rudolph <i>et al.</i> (1999) "Longevity, Stress Response, and Cancer in Aging Telomerase-Deficient Mice," <i>Cell</i> 96:701-12	
DEC 02 2002 TRADEMARK	28	Greenberg <i>et al.</i> (1999) "Short Dysfunctional Telomeres Impair Tumorigenesis in the INK4a <sup>AS</sup> Cancer-Prone Mouse," <i>Cell</i> 97:515-25	
	29	Morales <i>et al.</i> (1999) "Absence of cancer-associated changes in human fibroblasts immortalized with telomerase," <i>Nature Genetics</i> 21:115-8	
	30	Hahn <i>et al.</i> (1999) "Creation of human tumour cells with defined genetic elements," <i>Nature</i> 400:464-8	
	31	Broccoli <i>et al.</i> (1995) "Telomerase activity in normal and malignant hematopoietic cells," <i>Proc. Natl. Acad. Sci. USA</i> 92:9993-6	
	32	Shay <i>et al.</i> (1997) "A Survey of Telomerase Activity in Human Cancer," <i>Eur. J. Cancer</i> 33:787-91	
	33	Kim (1997) "Clinical Implications of Telomerase in Cancer," <i>Eur. J. Cancer</i> 33:781-6	
	34	Nakamura <i>et al.</i> (1997) "Telomerase Catalytic Subunit Homologs from Fission Yeast and Human," <i>Science</i> 277:955-8	
	35	Marx (1993) "How p53 Suppresses Cell Growth." <i>Science</i> 262:1644-5	
	36	Disis <i>et al.</i> (1997) "HER-2/neu Protein: A Target for Antigen-Specific Immunotherapy of Human Cancer," <i>Adv. Cancer Res.</i> 71:343-71	
	37	Walker <i>et al.</i> (1988) "HIV-1 Reverse Transcriptase Is a Target for Cytotoxic T Lymphocytes in Infected Individuals," <i>Science</i> 240:64-6	
	38	Schwartz (1990) "A Cell Culture Model for T Lymphocyte Clonal Anergy," <i>Science</i> 248:1349-56	
	39	Firat <i>et al.</i> (1999) "H-2 class I knockout, HLA-12.1-transgenic mice: a versatile animal model for preclinical evaluation of antitumor immunotherapeutic strategies," <i>Eur. J. Immunol.</i> 29:3112-21	
	40	Lee (1990) in <i>The HLA System</i> , ed. Lee, J. (Springer-Verlag, NY), pp 141-178	
	41	Fernandez-Vina <i>et al.</i> (1992) "DNA Typing for HLA Class I Alleles, 1. Subsets of HLA-A2 and of -A28," <i>Human Immunol.</i> 33:163-73	
	42	Krausa <i>et al.</i> (1995) "Genetic polymorphism within HLA-A*02: significant allelic variation revealed in different populations," <i>Tissue Antigens</i> 45:223-31;	
	43	Ruppert <i>et al.</i> (1993) "Prominent Role of Secondary Anchor Residues in Peptide Binding to HLA-A2.1 Molecules," <i>Cell</i> 74:929-37;	
	44	Parker <i>et al.</i> (1994) "Scheme for Ranking Potential HLA-A2 Binding Peptides Based on Independent Binding of Individual Peptide Side-Chains," <i>J. Immunol.</i> 152:163-75	
	45	Vitiello <i>et al.</i> (1991) "Analysis of the HLA-restricted Influenza-specific Cytotoxic T Lymphocyte Response in Transgenic Mice Carrying a Chimeric Human-Mouse Class I Major Histocompatibility Complex," <i>J. Exp. Med.</i> 173:1007-15	
	46	Sette <i>et al.</i> (1994) "The Relationship Between Class I Binding Affinity and Immunogenicity of Potential Cytotoxic T Cell Epitopes," <i>J. Immunol.</i> 153:5586-92	
	47	van der Burg <i>et al.</i> (1996) "Immunogenicity of Peptides Bound to MHC Class I Molecules Depends on the MHC-Peptide Complex Stability," <i>J. Immunol.</i> 156:3308-14	
	48	Sommerfeld <i>et al.</i> (1996) "Telomerase Activity: A Prevalent Marker of Malignant Human Prostate Tissue," <i>Cancer Res.</i> 56:218-22	
	49	Hunt <i>et al.</i> (1992) "Characterization of Peptides Bound to the Class I MHC Molecule HLA-A2.1 by Mass Spectrometry," <i>Science</i> 1261-3	
	50	Quaranta <i>et al.</i> (1982) "A Recurrent Idiotypic on Monoclonal Anti-Human IgA Antibodies," <i>J. Exp. Med.</i> 156:1551-6	
	51	Zanetti <i>et al.</i> (1993) "Expression of conformationally constrained adhesion peptide in an antibody CDR loop and inhibition of natural killer cell cytotoxic activity by an antibody antigenized with the RGD motif," <i>EMBO J.</i> 12:4375-4384	
	52	Hiyama <i>et al.</i> (1995) "Activation of Telomerase in Human Lymphocytes and Hematopoietic Progenitor Cells," <i>J. Immunol.</i> 155:3711-15	
	53	Pascolo <i>et al.</i> (1997) "HLA-A2.1-restricted Education and Cytolytic Activity of CD8 <sup>+</sup> T Lymphocytes from β2 Microglobulin (β2m) HLA-A2.1 Monochain Transgenic H-2D <sup>+</sup> β2m Double Knockout Mice," <i>J. Exp. Med.</i> 185:2043-51	
	54	Doyle <i>et al.</i> (1985) "Markedly Decreased Expression of Class I Histocompatibility Antigens, Protein, and mRNA in Human Small-Cell Lung Cancer," <i>J. Exp. Med.</i> 161:1135-51	
Examiner:	<i>J. Lee</i>		Date Considered: <i>8/23/04</i>
EXAMINER:	Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

FORM PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No.: UCSD-02424	Serial No.: 08/723,052
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary)  (37 CFR § 1.98(b))				Applicant: Mario Chojkier <i>et al.</i>	
				Filing Date: 09/30/96	Group Art Unit:
OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)					
55	Momburg <i>et al.</i> (1986) "Loss of HLA-A,B,C and <i>De Novo</i> Expression of HLA-D in Colorectal Cancer," <i>Int. J. Cancer</i> 37:179-84				
56	Restifo <i>et al.</i> (1993) "Identification of Human Cancers Deficient in Antigen Processing," <i>J. Exp. Med.</i> 177:153-7				
57	Cromme <i>et al.</i> (1994) "Loss of Transporter Protein, Encoded by the TAP-1 Gene, is Highly Correlated with Loss of HLA Expression in Cervical Carcinomas," <i>J. Exp. Med.</i> 179:335-40				
58	Rosenberg <i>et al.</i> (1998) "Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma," <i>Nature Med.</i> 4:321-27				
59	Nestle <i>et al.</i> (1998) "Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells," <i>Nature Med.</i> 4:328-332				
60	Thomson <i>et al.</i> (1998) "Delivery of Multiple CD8 Cytotoxic T Cell Epitopes by DNA Vaccination," <i>J. Immunol.</i> 160:1717-23				
61	Sykulev <i>et al.</i> (1996) "Evidence that a Single Peptide-MHC Complex on a Target Cell Can Elicit a Cytolytic T Cell Response," <i>Immunity</i> 4:565-71				
62	Morgan <i>et al.</i> (1998) "Activation of Low Avidity CTL Specific for a Self Epitope Results in Tumor Rejection But Not Autoimmunity," <i>J. Immunol.</i> 160:643-51				
63	Overwijk <i>et al.</i> (1999) "Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: Requirement for CD4 <sup>+</sup> T lymphocytes," <i>Proc. Natl. Acad. Sci. USA</i> 96:2982-7				
64	Hu <i>et al.</i> (1993) "An Evaluation of the Potential to Use Tumor-associated Antigens as Targets for Antitumor T Cell Therapy Using Transgenic Mice Expressing a Retroviral Tumor Antigen in Normal Lymphoid Tissues," <i>J. Exp. Med.</i> 177:1681-90				
65	Uyttenhove <i>et al.</i> (1997) "The Expression of Mouse Gene PIA In Testis Does Not Prevent Safe Induction of Cytolytic T Cells Against a PIA-Encoded Tumor Antigen," <i>Int. J. Cancer</i> 70:349-56				
66	Falk <i>et al.</i> (1991) "Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules," <i>Nature</i> 351:290-6				
67	Rotzschke <i>et al.</i> (1990) "Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells," <i>Nature</i> 348:252-254				
68	Schumacher <i>et al.</i> (1991) "Peptide selection by MHC class I molecules," <i>Nature</i> 350:703-6				
Examiner: <i>S. Gurn</i>		Date Considered: 8/23/04			
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

